Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Critical Literature Analysis: 3 Recent Journal Articles
|
|
- Dwight Robertson
- 6 years ago
- Views:
Transcription
1 Critical Literature Review: Diabetes Therapeutics November 7 th, 2013 Jason Gaglia MD, MMSc Assistant Investigator, Joslin Diabetes Center Assistant Professor, Harvard Medical School Specific Therapeutics to be Discussed Insulin Glargine and Cancer Risk Pioglitizone and Bladder Cancer Risk Incretin Mimetics, Pancreatitis, and Pancreatic Cancer Development of Insulin Analogs Sequences of Various Insulins (natural and analogs) A-Chain Position B-Chain Position Insulin A-8 A-10 A-21 B-3 B-10 B-28 B-29 B30 B-31/32 Human Thr Ilc Asn Asn His Pro Lys Thr N/A Bovine Ala Val Asn Asn His Pro Lys Ala N/A Porcine Thr Ilc Asn Asn His Pro Lys Ala N/A (also dog) Aspart Thr Ilc Asn Asn His Asp Lys Thr N/A Glulisine Thr Ilc Asn Lys His Pro Glu Thr N/A Lispro Thr Ilc Asn Asn His Lys Pro Thr N/A Detemir Thr Ilc Asn Asn His Pro Lys Myristic acid N/A Glargine Thr Ilc Gly Asn His Pro Lys Thr Arg/Arg B10Asp Thr Ilc Asn Asn Asp Pro Lys Thr N/A 1
2 Mitogenic Potential of Insulin Analogs Insulin B10Asp was the first of the insulin analogs developed. It has higher affinity for the insulin and IGF-1 receptors than native insulin, and higher mitogenicity in vitro. Insulin (U/kg/day) Mammary Tumors Saline Human 200 B10Asp 12.5 B10Asp 50 B10Asp 200 Benign % 0 44% Malignant % 23% Female rats were injected for one year with saline or insulin as indicated. A dosedependent increase in incidence of mammary tumors was found on necropsy. No other neoplastic lesions were found. Jorgensen LN et al. Diabetologia. 1992;35(Suppl 1):A3. Conclusions/interpretation Considering the overall relationship between insulin dose and cancer, and the lower dose with glargine, the cancer incidence with glargine was higher than expected compared with human insulin. Our results based on observational data support safety concerns surrounding the mitogenic properties of glargine in diabetic patients. Prospective long-term studies are needed to further evaluate the safety of insulin analogs, especially glargine. Hemkens LG et al. Diabetologia. 2009;52: Mitogenic Potential of Insulin Analogs Analog Insulin Receptor Affinity (%) Insulin Receptor Off-Rate (%) Metabolic Potency (Lipogenesis) (%) IGF-1 Receptor Affinity (%) Mitogenic Potency (%) Human B10Asp 205 ± ± ± ± ± 173 Aspart 92 ± 6 81 ± ± 2 81 ± 9 58 ± 22 Lispro 84 ± ± ± ± ± 10 Glargine 86 ± ± ± ± ± 132 A21Gly 78 ± ± ± 3 42 ± ± 12 B31B32diArg 120 ± 4 75 ± 8 75 ± ± ± 390 Adapted from Kurtzhals PK et al. Diabetes. 2000;49:
3 Back to the Article Hemkens and colleagues utilized a large German insurance dataset to compare the rate of diagnosis of malignant tumors in patients treated with human insulin versus the insulin analogs aspart, lispro, and glargine. Those treated with multiple types of insulin were excluded. Included 127,031 individuals (39% of all those using insulin) 95,804 (75.4%) exclusively on human insulin 23,855 (18.8%) insulin glargine alone 4,103 (3.2%) insulin aspart alone 3,269 (2.6%) insulin lispro alone Hemkens LG et al. Diabetologia. 2009;52: The German Study (continued) First time insulin users, no evidence of malignancy for prior 3 years Type of diabetes (1 or 2) was not specified in the registry, weight not specified in the registry Primary outcome was malignancy of any type; secondary outcome was all cause mortality Mean follow up was 1.63 years for malignancy (maximum 4.41) and 1.67 years for mortality (maximum 4.41) Median age about 67 years Hemkens LG et al. Diabetologia. 2009;52: Crude Malignancy and Mortality Rates Insulin Time (yrs) Malignancy Rate (per 100 pt-yrs) Insulin Dose (U) Mortality Rate (per 100 pt-yrs) Mean ± SD Human ± Aspart 1.44* ± Lispro ± Glargine 1.31* ± *Mean duration of follow-up for glargine and aspart was shorter as these insulins were introduced to the German market later. Hemkens LG et al. Diabetologia. 2009;52:
4 HRs for Malignant Neoplasms Referenced to Human Insulin Covariate Aspart Lispro Glargine None 0.86 ( ) 0.85 ( ) 0.85 ( ) Final Model P=0.30 P=0.96 P< U 1.00 ( ) 0.99 ( ) 1.09 ( ) 30 U 1.02 ( ) 0.98 ( ) 1.19 ( ) 50 U 1.04 ( ) 0.98 ( ) 1.31 ( ) Hemkens LG et al. Diabetologia. 2009;52: HRs for Mortality Referenced to Human Insulin Covariate Aspart Lispro Glargine None 0.63 ( ) 0.75 ( ) 0.68 ( ) Final Model P=0.14 P=0.47 P< U 0.91 ( ) 0.96 ( ) 0.76 ( ) 30 U 0.90 ( ) 0.95 ( ) 0.96 ( ) 50 U 0.89 ( ) 0.94 ( ) 1.20 ( ) Hemkens LG et al. Diabetologia. 2009;52: Metabolism of Insulin Glargine Native insulin Insulin glargine A21Gly insulin A21Gly-des-30B-Thr After subcutaneous injection, insulin glargine is metabolized by sequential cleavage at the carboxy terminus of the B chain, yielding products including A21Gly and A21Gly-des- 30B-Thr insulins. On average about 50% of insulin recovered from fat from the site of injection are these two cleavage products and these products are also present and produced in the circulation after injection. A21Gly insulin has relatively low mitogenic potency. Kuerzel GU et al. Curr Med Res Opin. 2003;18: Agin A et al. Diabetes Metab. 2007;33: Kurtzhals PK et al. Diabetes. 2000;49:
5 Mitogenic Potential of Insulin Analogs Analog Insulin Receptor Affinity (%) Insulin Receptor Off-Rate (%) Metabolic Potency (Lipogenesis) (%) IGF-1 Receptor Affinity (%) Mitogenic Potency (%) Human B10Asp 205 ± ± ± ± ± 173 Aspart 92 ± 6 81 ± ± 2 81 ± 9 58 ± 22 Lispro 84 ± ± ± ± ± 10 Glargine 86 ± ± ± ± ± 132 A21Gly 78 ± ± ± 3 42 ± ± 12 B31B32diArg 120 ± 4 75 ± 8 75 ± ± ± 390 Adapted from Kurtzhals PK et al. Diabetes. 2000;49: Limitations of Observational Studies Large potential for bias The clinical decisions that determine each patient s treatment are not random Difficult to adjust for confounders Residual selection bias may distort any true differences (or lack thereof) Issues of reverse causality Multiple hypothesis testing may produce spurious results Small RCT Post Hoc Analysis Original study designed to assess ocular complications of diabetes with insulin glargine compared to NPH insulin (no difference seen) 1017 patients randomized and treated: 514 insulin glargine, 503 NPH insulin Cumulative exposure was greater than 4 years Baseline demographics between the two groups were similar No difference in number of neoplasms between the two groups (57 or 11.1% for insulin glargine and 62 or 12.3% for NPH insulin) Rosenstock J et al. Diabetologia. 2009;52:
6 RCT ORIGIN Trial Insulin glargine versus placebo in patients with impaired fasting glucose or newly diagnosed type 2 diabetes. 12,537 people randomized with median follow-up of 6.2 years. Median insulin use at year 6 was 0.4 U/kg. No significant difference in cancers (HR 1.00; 95% CI, 0.88 to 1.13; P=0.97) or death from cancers (HR 0.94; 95% CI, 0.77 to 1.15; P=0.52). ORIGIN Trial Investigators. N Engl J Med. 2012;367: Specific Therapeutics to be Discussed Insulin Glargine and Cancer Risk Pioglitizone and Bladder Cancer Risk Incretin Mimetics, Pancreatitis, and Pancreatic Cancer 6
7 Background Data on TZDs and Cancer PPAR ligands alter cell proliferation and differentiation in human cancer cell lines, including bladder cancer cells. Early studies suggested antitumor effects of PPAR activation in human cancer cell lines In male rats, pioglitazone treatment associated with more bladder tumors compared to placebo (not seen in female rats, mice of either sex or other organs). Bladder tumors reported with combined PPAR and agonists in rats. _Product_Information/human/000285/WC pdf. Suzuki et al. Toxicol Sci. 2010; PMID The European Data Retrospective cohort study using data from the French National Health Insurance Plan with 1.5 million patients with diabetes, followed for up to 4 years ( ). No difference in unadjusted analysis. After adjusting for age, sex, and use of other anti-diabetic medications (but not smoking), statistically significant increase in the risk for bladder cancer in patients exposed to pioglitazone compared to other anti-diabetic agents (HR 1.22; 95% CI 1.03 to 1.43). The results showed a dose effect related to cumulative dose >28,000 mg (HR 1.75; 95% CI 1.22 to 2.5) and for exposures longer than 1 year (HR 1.34; 95% CI 1.02 to 1.75). Neumann J et al. Diabetologia. 2012;55: nd_events/news_and_events.jsp&mid=wc0b01ac058004d5c1&jsenabled=true The American Data Planned five-year interim analysis (1/1997 through 4/2008) of tenyear, observational cohort study in patients with diabetes who are members of Kaiser Permanente Northern California (KPNC) health plan which includes 193,099 patients with diabetes. No difference in unadjusted analysis. After adjustments including age, sex, race/ethnicity, diabetes medications, A1C, and smoking, use of pioglitazone was not associated with risk of bladder cancer (HR 1.2 [95% CI ]). However, in the a priori category of >24 months of therapy, there was an increased risk (1.4 [ ]). Ninety-five percent of cancers diagnosed among pioglitazone users were detected at early stage. Lewis JD et al. Diabetes Care. 2011;34:
8 Diabetes and Excess Cancer Risk Type 2 diabetes, significant excess cancer risk: Breast 20% Colorectal 30% Endometrium 110% Liver 150% Bladder 24% Pancreas 40% Type 1 diabetes, modest excess cancer risk: Stomach Cervix Endometrium Larson SC et al. Int J Cancer. 2007;121: (2007). Larson SC et al. J Natl Cancer Inst. 2005;97: Huxley R et al. Br J Cancer. 2005;92: ). Zendehdel K et al. J Natl Cancer Inst. 2003;95: El- Serag HB et al. Clin Gastroenterol Hepatol. 2006;4: Larson SC et al. Eur J Cancer. 2008;44: Adami HO et al. Cancer Causes Control. 1991;2: Ferrera A et al. Diabetes Care. 2011;34: Other Studies: Azoulay et al. Nested case control study. Pioglitazone associated with increased rate of bladder cancer 1.83 [95% CI ]. Function of duration, exposed > 24 months 1.99 [95% CI 1.14 to 3.45] and dosage, > 28,000 mg 2.54 [95% CI 1.05 to 6.14]. Participants prescribed thiazolidinediones were more likely to be obese, to have ever smoked, and to have uncontrolled diabetes. Wei et al. Propensity score matched cohort study. 23,548 exposed to pioglitizone and 184,166 other diabetes medications. Pioglitazone did not increase the risk of bladder cancer. HR 1.16 [95% CI 0.83 to 1.62]. Chang et al. Case-control study. Pioglitazone use not associated with bladder cancer, associated with significantly lower risk of liver cancer OR 0.83 [95% CI ]. Protective effects were stronger for higher cumulative dosage and longer duration. Azoulay L et al. BMJ. 2012;344e3645. Wei L et al. Br J Clin Parmacol. 2013;75: Change CH et al. Hepatology. 2012;55:
9 Aging Obesity Diet Physical Inactivity Smoking Diabetes and Cancer: Shared Risk Factors Is There Any Evidence from Randomized Controlled Trials? PROactive: Adverse Events Dormandy JA et al. Lancet. 2005;366:
10 June 15, 2011 Specific Therapeutics to be Discussed Insulin Glargine and Cancer Risk Pioglitizone and Bladder Cancer Risk Incretin Mimetics, Pancreatitis, and Pancreatic Cancer April 19, 2012 Public Citizen, representing more than 250,000 members and supporters nationwide, hereby petitions the Food and Drug Administration (FDA), pursuant to the Federal Food, Drug, and Cosmetic Act (FDCA) 21 U.S.C. 355(e) and 21 C.F.R , to immediately remove from the market the diabetes drug liraglutide (Victoza; Novo Nordisk) because the known increased risks of thyroid cancer and pancreatitis, both of which occurred in people enrolled in preapproval clinical trials, outweigh any documented clinical benefits. 10
11 Incretin Mimetics and Cancer (medullary thyroid) Long term dosing with GLP 1 receptor agonists causes C cell hyperplasia and tumor formation in rodents. 20 months of liraglutide treatment (at >60 times human exposure levels) did not lead to C cell hyperplasia in monkeys. GLP 1R Expression in Normal Thyroid Normal Thyroid GLP 1R Localization Method Species Mouse Rat Human Autoradiographic Ligand Binding 3/5 5/5 12/12 8/8 1/18 0/13 0/6 In situ Hybridization ND ND 0/10 Immunohistochemistry /9* *Histologically normal thyroid without multinodular goiter or inflammation. Staining noted in multinodular goiter (3/3) and/or thyroid with lymphocytic infiltrate (3/4). Körner M et al. J Nucl Med. 2007;48: Knudsen LB et al. Endocrinology. 2010;151: Gier B et al. J Clin Endocrinol Metab. 2012;97: Waser B et al. Neuroendocrinology. 2011;94: GLP 1R Expression Method Tumor Type RET Autoradiographic Ligand Binding Pancreatic Adenocarcinoma Immunohistochemistry Medullary Thyroid carcinonma 5/18 10/36 Papillary Thyroid carcinoma Pheo germline mutations ND 0/21 12/20 ND 6/12* 3/17 ND ND 5/5 *With 10% positive cells and calcitonin colocalization otherwise 11/12 total. Reactive C-cell hyperplasia 1/4 with 10% positive cells and calcitonin colocalization otherwise 4/4 total. Körner M et al. J Nucl Med. 2007;48: Gier B et al. J Clin Endocrinol Metab. 2012;97: Waser B et al. Neuroendocrinology. 2011;94:
12 Calcitinon Levels in LEAD Studies 10 9 Upper Normal Range Males Upper Normal Range Females Liraglutide 0.6 mg Liraglutide 1.2 mg Liraglutide 1.8 mg Active comparator Placebo /28 39/ /65 76/78 91/92 Weeks 104 Hegedüs L et al. J Clin Endocrinol Metab, 2010;96: Incretin Mimetics and Cancer (medullary thyroid) No evidence of C cell stimulation as assessed by calcitonin analysis after 2 years of human liraglutide exposure. No evidence of an increase in medullary thyroid cancer after 840,000 patient years of exanatide exposure in humans. Knudsen LB et al. Endocrinology. 2010;151: Hegedüs L et al. J Clin Endocrinol Metab, 2010;96: January 25, 2010 It is not known if Victoza could cause thyroid tumors or a very rare type of thyroid cancer called medullary thyroid cancer in people. For this reason, Victoza should not be used as the first line treatment for diabetes until additional studies are completed that support expanded use. Victoza should not be used in people already at risk for medullary thyroid cancer, such as those who have medullary thyroid cancer in the family or those with a rare genetic condition known as Multiple Endocrine Neoplasia syndrome type 2. Required company to conduct a 5 year epidemiological study to evaluate thyroid and other cancer risks and establish a cancer registry to monitor the rate of medullary thyroid cancer in the United States over the next 15 years. 12
13 Incretin Mimetics and Pancreatitis Pancreatitis and Type 2 Diabetes Incidence per 100,000 patient-years Noel RA et al. Diabetes Care. 2009; 32: Acute Pancreatitis with Liraglutide versus Active Comparator Liraglutide Active comparator Safety analysis set (n) Total exposure (years) Events (n) 5 1 Events/1000 patient years Liraglutide injection prescribing information, Novo Nordisk,
14 March 14, 2013 The U.S. Food and Drug Administration (FDA) is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics. These findings were based on examination of a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes. FDA has asked the researchers to provide the methodology used to collect and study these specimens and to provide the tissue samples so the Agency can further investigate potential pancreatic toxicity associated with the incretin mimetics. FDA previously warned the public about postmarketing reports of acute pancreatitis, including fatal and serious nonfatal cases, associated with the use of the incretin mimetic drugs exenatide and sitagliptin. A recently published study that examined insurance records also found the use of exenatide or sitagliptin could double the risk of developing acute pancreatitis. The Warnings and Precautions section of the drug labels and the patient Medication Guides for incretin mimetics contain warnings about the risk of acute pancreatitis. FDA has not previously communicated about the potential risk of pre-cancerous findings of the pancreas with incretin mimetics. Further, FDA has not concluded these drugs may cause or contribute to the development of pancreatic cancer. Results The mean age of included individuals was 52 years, and 57.45% were male. Cases were significantly more likely than controls to have hypertriglyceridemia (12.92% vs 8.35%), alcohol use (3.23% vs 0.24%), gallstones (9.06% vs 1.34), tobacco abuse (16.39% vs 5.52%), obesity (19.62% vs 9.77%), biliary and pancreatic cancer (2.84% vs 0%), cystic fibrosis (0.79% vs 0%), and any neoplasm (29.94% vs 18.05%). After adjusting for available confounders and metformin hydrochloride use, current use of GLP-1 based therapies within 30 days (adjusted odds ratio, 2.24 [95% CI, ]) and recent use past 30 days and less than 2 years (2.01 [ ]) were associated with significantly increased odds of acute pancreatitis relative to the odds in nonusers. Conclusions and Relevance In this administrative database study of US adults with type 2 diabetes mellitus, treatment with the GLP-1 based therapies sitagliptin and exenatide was associated with increased odds of hospitalization for acute pancreatitis. Singh S et al. JAMA Internal Med. 2013; Online Feb 25. Unadjusted Numbers Characteristic Cases n=1269 Controls n=1269 Ratio (cases/controls) Hypertriglyceridemia 164 (12.9) 106 (8.4) 1.5 Alcohol use 41 (3.2) 30 (0.2) 1.4 Gallstones 115 (9.1) 17 (1.3) 6.8 Tobacco use 208 (16.4) 70 (5.5) 3.0 Obesity 249 (19.6) 124 (9.8) 2 Biliary/pancreatic ca 36 (2.8) 0 Cystic fibrosis 10 (0.8) 0 Current GLP 1 therapy 55 (4.3) 42 (3.3) 1.3 Recent GLP 1 therapy 72 (5.7) 48 (3.8) 1.5 Singh S et al. JAMA Internal Med. 2013; Online Feb
15 The American Association of Clinical Endocrinologists (AACE) and the American Diabetes Association believe that the study by Singh et al, Glucagon-like Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus, published online February 25th in JAMA Internal Medicine does not provide the basis for changing treatment in people with diabetes. Fortunately, there will be new data available relatively soon which will allow physicians to definitively assess risks and benefits of this class of medicines. The analysis is a retrospective study using data from an administrative database. This type of analysis is not considered as robust as a prospective randomized controlled clinical trial, the gold standard for evaluating treatments. There are currently nine ongoing, prospective, controlled trials of GLP-1 based therapy with over 65,000 subjects, which should provide answers to these important safety questions. While there are risks and benefits associated with any therapy, the retrospective analysis indicates GLP-1 based therapies are associated with a relatively small excess risk of hospitalization for acute pancreatitis, with only two additional cases per 100 patients over a three-year period. This same population of adults, between the ages of with type 2 diabetes, had a greater risk of hospitalization for acute pancreatitis if they used tobacco, consumed alcohol or were obese. As with any therapy, we encourage patients to speak with their doctors to assess which treatments are best for them and to not stop therapy on their own without consulting their doctors. Proposed Pancreatitis Mechanisms High risk population (obesity, diabetes, tobacco, alcohol, gallstones, hypertriglyceridemia) Weight loss Increased pancreatic duct cell replication and acinar to ductal metaplasia Development of Pancreatic Cancer Normal Premalignant (PanIN) Cancer KRAS2 p16/cdkn2a TP53 SMAD4 BRCA2 Gier B and Butler P. JAMA Intern Med. 2013; Online March 5 15
16 Animal and In Vitro Studies Novo Nordisk In mice, after 2 years microscopic pancreatitis in 3/158 (2%) control and 17/555 (3%) liraglutide tx. In rats, after 2 years no pancreatitis 0/100 control, 0/299 tx. In monkeys after 2 years no pancreatitis 0/10 control, 0/19 tx. In 87 week monkey study at 6 mg/kg/day no PanIN in ductal epithelium seen (0/10 animals). Peter Butler In rats, treatment with exendin 4 induces expansion of pancreatic duct glands without pancreatitis. In rats, after exendin 4 tx mucinous metaplasia and columnar cell atypia resembling low grade PanIN is seen (no carcinomas). In Pdx1 Kras mice after exendin 4 there was extensive acinar to ductal metaplasia and increased PanIN. Treatment of human pancreatic duct cells (HPDE) induced cyclin D1. Metformin was protective in Kras mutant HPDE cells (pcreb/creb). Nyborg N et al. Diabetes. 2012;61: Gier B et al. Diabetes. 2012;61: Marked Expansion of Exocrine and Endocrine Pancreas with Incretin Therapy in Humans with Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors Controversy exists regarding the potential regenerative influences of incretin therapy on pancreatic cells versus possible adverse pancreatic proliferative effects. Examination of pancreata from age matched organ donors with type 2 diabetes (DM) treated by incretin therapy (n=8) or other therapy (n=12) and non diabetic controls (n=14) reveals a ~40% increased pancreatic mass in DM treated with incretin therapy with both increased exocrine cell proliferation (p<0.0001) and dysplasia (increased pancreatic intraepithelia neoplasia, p<0.01). Pancreas in DM treated with incretin therapy was notable for α cell hyperplasia and glucagon expressing microadenomas (3/8) and a neuroendocrine tumor. β-cell mass was reduced by approximately 60% in those with DM, yet a 6 fold increase was observed in incretin treated subjects although diabetes persists. Endocrine cells co-staining for insulin and glucagon were increased in DM compared to non diabetic controls (p<0.05) and markedly further increased by incretin therapy (p<0.05). In conclusion, in humans, incretin therapy resulted in a marked expansion of the exocrine and endocrine pancreatic compartments, the former being accompanied by increased proliferation and dysplasia, the latter by α cell hyperplasia with the potential for evolution into neuroendocrine tumors. Butler AE et al. Diabetes. 2013;Mar 22 Epub. PMID Male, 2 Female 7 Januvia, 1 Byetta Over 50: 5/8 (63%) Butler AE et al. Diabetes. 2013;Mar 22 Epub. PMID
17 4 Male, 8 Female 4 insulin treated 5 no treatment Over 50: 2/12 (17%) Butler AE et al. Diabetes. 2013;Mar 22 Epub. PMID Male, 7 Female Over 50: 4/14 (29%) Butler AE et al. Diabetes. 2013;Mar 22 Epub. PMID Sitagliptin Effects on the Pancreas? A 1.5 cm α-cell/glucagon producing neuroendocrine tumor (Grade 1, World Health Organization, 2010) not appreciated in life was identified in the body of the pancreas after resection at brain death. Glucagon-producing microadenomas were also detected in the same case (6185) and two other incretin treated cases (6157 and 6206). Increase in the presence of pancreatic intraepithelial neoplasia (PanINs) (11.9±2.6 vs 4.9±1.7, DM-I vs DM, PanINs/mm 2 x 103, p<0.01). Butler AE et al. Diabetes. 2013;Mar 22 Epub. PMID
18 Beta Cell % Then and Now Butler AE et al. Diabetes. 2003;52: PMID Butler AE et al. Diabetes. 2013;Mar 22 Epub. PMID PanINs are rarely seen before age 35, but are found in 60% by age 45 and in 75% of individuals by age 55. Harja E et al. Diabetes Technology & Therapeutics. 2013;8: Andea A et al. Mod Pathol. 2003;16: What are the risk factors for pancreatic cancer: Age The risk of developing pancreatic cancer increases as people age. Almost all patients are older than 45. Nearly 9 in 10 are at least 55 years old and almost 7 in 10 are at least 65 years old. The average age at the time of diagnosis is 71. Sex Men are 30% more likely to develop pancreatic cancer than women. Race African Americans are more likely to develop pancreatic cancer. Smoking About 20% to 30% of exocrine pancreatic cancer cases are thought to be caused by cigarette smoking. Other: Chronic Pancreatitis, Obesity, Diabetes, Cirrhosis, Family History, Occupational Exposures, Heavy Alcohol Consumption 18
19 Critiques after the Butler Paper Harja et al. From this, we conclude that the data and the implications of the data, as expressed by Butler et al., are vastly overstated and seemingly irresponsibly articulated. Their analysis seems to be more of an alarmist perspective, creating controversy rather than a neutral and fact-based approach. At the core of the discussion are limited numbers and many confounders related to subject history, presentation, and other subject-specific factors that make their conclusions invalid. European Medicines Agency No new concerns for GLP-1 therapies identified on the basis of available evidence. FDA had conversations with EMA and was aware of their analyses regarding the potential pancreatic effects of GLP-1 based therapies. Our general view is that their conclusions are consistent with our current understanding of the data. Harja E et al. Diabetes Technology & Therapeutics. 2013;8: European Medicines Agency. July 26, Where are we now? European Medicines Agency two large independent studies have been under way since 2011 to study the risk profile of diabetes treatment in general, and more specifically their risk profile in relation to the pancreas. First results of these studies, which are funded by the European Commission, are expected in the spring of Food and Drug Administration FDA's review is ongoing as pancreatitis and pancreatic cancer data are being collected in the cardiovascular outcome trials being conducted with this class of drugs. Additionally, there is an ongoing epidemiological study. 19
Increased risk of cancer with anti-diabetes drugs? : pros
24 th Spring Congress of Korean Diabetes Association Increased risk of cancer with anti-diabetes drugs? : pros Nan Hee Kim, MD, Ph.D. Professor Korea University Medical School Contents Diabetes and cancer
More informationType 2 Diabetes and Cancer: Is there a link?
Type 2 Diabetes and Cancer: Is there a link? Sonali Thosani, MD Assistant Professor Department of Endocrine Neoplasia & Hormonal Disorders MD Anderson Cancer Center No relevant financial disclosures Objectives
More informationThiazolidinediones and the risk of bladder cancer: A cohort study. R Mamtani, K Haynes, WB Bilker, DJ Vaughn, BL Strom, K Glanz, JD Lewis
Thiazolidinediones and the risk of bladder cancer: A cohort study R Mamtani, K Haynes, WB Bilker, DJ Vaughn, BL Strom, K Glanz, JD Lewis Study objective To investigate the risk of bladder cancer associated
More informationGastroenterology Attn.: Editor-in-Chief Anil K. Rustgi University of Pennsylvania Philadelphia
Gastroenterology Attn.: Editor-in-Chief Anil K. Rustgi University of Pennsylvania Philadelphia gastro@gastro.org, anil2@mail.med.upenn.edu Potentially damaging controversial analysis to be published in
More informationCase 3: Pancreatitis Risk with Incretin Therapies: Is It Real? Case: Pancreatitis Risk with Incretin Therapy
Case 3: Pancreatitis Risk with Incretin Therapies: Is It Real? Case: Pancreatitis Risk with Incretin Therapy 43-year-old obese woman Long-standing type 2 diabetes Currently treated with metformin 1000
More informationIncreased Risk of Cancer with Anti-diabetes Drugs? Cons
Increased Risk of Cancer with Anti-diabetes Drugs? Cons Inje University College of Medicine, Ilsanpaik Hospital, Department of Internal Medicine Dong-Jun Kim Gastroenterology132:2208-2225, 2007 IGF-1 System
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationCohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ 2013;346:f3680
Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ 2013;346:f3680 Webappendix 7: Correspondence between the BMJ and the manufacturers or marketers of sitagliptin,
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationFinal Report 22 January 2014
Final Report 22 January 2014 Cohort Study of Pioglitazone and Cancer Incidence in Patients with Diabetes Mellitus, Follow-up 1997-2012 Kaiser Permanente Division of Research Assiamira Ferrara, MD, Ph.D.
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationDPP-4 inhibitor use and risk of diabetic retinopathy: a new safety issue of a safe drug Nam Hoon Kim
DPP-4 inhibitor use and risk of diabetic retinopathy: a new safety issue of a safe drug Nam Hoon Kim Endocrinology of Metabolism, Korea University College of Medicine Conflict of interest disclosure None
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationSelect problems in cystic pancreatic lesions
Disclosure Select problems in cystic pancreatic lesions Five Prime Therapeutics shareholder Adicet Bio shareholder Bristol-Meyer Squibb advisory board grace.kim@ucsf.edu Pancreatic cystic lesions Intraductal
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationDR. SUBHASH K. WANGNOO
Photograph DR. SUBHASH K. WANGNOO M.D, D.M, FRCP (London) Senior Consultant, Endocrinologist & Diabetologist Apollo Centre for Obesity, Diabetes and Endocrinology Indraprastha Apollo Hospital, Sarita Vihar,
More informationp53 expression in invasive pancreatic adenocarcinoma and precursor lesions
Malaysian J Pathol 2011; 33(2) : 89 94 ORIGINAL ARTICLE p53 expression in invasive pancreatic adenocarcinoma and precursor lesions NORFADZILAH MY MBBCH,* Jayalakshmi PAILOOR MPath, FRCPath,* RETNESWARI
More informationPancreatic intraepithelial
Pancreatic intraepithelial neoplasia (PanIN) Markéta Hermanová St. Anne s University Hospital Brno Faculty of Medicine, Masaryk University Precursor lesions of invasive pancreatic cancer Pancreatic intraepithelial
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationPancreatobiliary Frozen Section Nightmares
Pancreatobiliary Frozen Section Nightmares Aatur D. Singhi, MD PhD Assistant Professor University of Pittsburgh Medical Center Department of Pathology singhiad@upmc.edu Objectives Briefly give an overview
More informationThey ve been touted as the new darlings
Has pancreatic damage from GLP-1 based diabetes drugs been underplayed? Incretin mimetics have been called the new darlings of diabetes treatment and they may soon also be licensed for treating obesity.
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationVictoza (liraglutide) solution for injection 6 mg/ml
Page: 1 of 11 Victoza (liraglutide) solution for injection 6 mg/ml Summary of the risk management plan (RMP) for Victoza Author: Novo Nordisk Pharma AG Page: 2 of 11 Table of Contents Page Table of Contents...
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationNew Drug Evaluation: lixisenatide injection, subcutaneous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)
Pancreas Quizzes Quiz 1 1. The pancreas produces hormones. Which type of hormone producing organ is the pancreas? a. Endocrine b. Exocrine c. Both A and B d. Neither A or B 2. Endocrine indicates hormones
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationApproaches to Addressing Incretin Deficiency. Non-Insulin Injectable Agents. Incretin Mimetics. Exendin-4 in the Gila Monster
Non-Insulin Injectable Agents Approaches to Addressing Incretin Deficiency Longer-acting analogs? (Incretin mimetics) GLP-1 Analogs Inhibition of inactivation? (Incretin enhancers) DPP-4 Inhibitors Drucker
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationCADTH Optimal use report
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Optimal use report Volume 3, Issue 1D July 2013 Optimal Use Recommendations
More informationORIGINAL INVESTIGATION. Glucagonlike Peptide 1 Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus
ORIGINAL INVESTIGATION Glucagonlike Peptide 1 Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus A Population-Based Matched Case-Control Study Sonal Singh, MD,
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationHong Qiu ALL RIGHTS RESERVED
2011 Hong Qiu ALL RIGHTS RESERVED ANTI-DIABETIC TREATMENT AND CANCER OCCURRENCE AMONG PATIENTS WITH TYPE II DIABETES MELLITUS By HONG QIU A dissertation submitted to the School of Public Health University
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationMore Diabetes Potpourri : Additional Current Issues Related to Diabetes
Page 1 Scott K. Stolte, Pharm.D. Associate Dean for Academic Affairs Bernard J. Dunn School of Pharmacy Shenandoah University This program has been brought to you by PharmCon Accreditation: Pharmacists:
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More informationGSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationCohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ 2013;346:f3680
Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ 2013;346:f3680 Webappendix 4: Correspondence between the BMJ and the manufacturers or marketers of liraglutide,
More informationMetformin. Sulfonylurea. Thiazolidinedione. Insulin
동아의대내분비내과박미경 Metformin Sulfonylurea Thiazolidinedione Insulin 요약 markers of inflammation (hs-crp, TNF-a) markers of impaired endothelial function (VFW, scams, tpa, PAI-1) LDL-C, fasting and postprandial
More informationT he clinical value of new therapies for
POINT-COUNTERPOINT (SEE ACCOMPANYING ARTICLES, PP. 1804, 1823, 2098, AND 2126) A Critical Analysis of the Clinical Use of Incretin-Based Therapies Are the GLP-1 therapies safe? There is no question that
More informationPapillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.
Papillary Lesions of the Breast A Practical Approach to Diagnosis (Arch Pathol Lab Med. 2016;140:1052 1059; doi: 10.5858/arpa.2016-0219-RA) Papillary lesions of the breast Span the spectrum of benign,
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationEndo 2 SLO Practice (online) Page 1 of 7
Endo 2 SLO Practice (online) Page 1 of 7 1. A long- acting insulin, like Lantus is for? A. When the next meal is within 30-60 minutes of the injection B. Over night use or for ½ of the day often combined
More informationClinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: Last Review Date: 02.
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: 03.01.18 Last Review Date: 02.19 Line of Business: HIM Revision Log See Important Reminder
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationDiabetes and cancer: two diseases with obesity as a common risk factor
Diabetes, Obesity and Metabolism 16: 97 110, 2014. 2013 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. Diabetes and cancer: two diseases with obesity as a common risk
More informationDrug Regulatory Affairs. Lyxumia. Summary of the Risk Management Plan (RMP) for Lyxumia (lixisenatide)
Drug Regulatory Affairs Lyxumia Summary of the Risk Management Plan (RMP) for Lyxumia (lixisenatide) Document version: 02 Document date: 08-Mar-2018 1 Summary of the risk management plan (RMP) for Lyxumia
More informationBeyond A1C. Non-glycemic Effects of GLP-1 Receptor Agonists. Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows
Beyond A1C Non-glycemic Effects of GLP-1 Receptor Agonists Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows Disclosures No conflicts of interest. Learning Objectives 1. Understand the physiological
More informationLong-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women with Type 2 Diabetes.
Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women with Type 2 Diabetes. Wu, J. W., Azoulay, L., Majdan, A., Boivin, J. F., Pollak, M., and Suissa, S. Journal of Clinical
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationTHE NEW-ISH DIABETES MEDICINES
THE NEW-ISH DIABETES MEDICINES Using GLP1s and SGLT2s FINANCIAL DISCLOSURES None Brent Jones, MD Endocrinology Madison Medical Affiliates January 31, 2019 OBJECTIVES Gain familiarity with GLP1 receptor
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More information3. Cardiovascular Disease?
Swiss recommendations 2016 Swiss Society of Endocrinology and Diabetology 1. Deficiency? Basal Premixed- Basal + GLP-1 RA (Xultophy ) or Basal Bolus 2. egfr < 30 ml/min? 3. Cardiovascular Disease? 4. Heart
More informationNeoplasias Quisticas del Páncreas
SEAP -Aproximación Práctica a la Patología Gastrointestinal- Madrid, 26 de mayo, 2006 Neoplasias Quisticas del Páncreas Gregory Y. Lauwers, M.D. Director, Service Massachusetts General Hospital Harvard
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationexenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited
exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationSHORT COMMUNICATION. J. C. Reubi & A. Perren & R. Rehmann & B. Waser & E. Christ & M. Callery & A. B. Goldfine & M. E. Patti
Diabetologia (2010) 53:2641 2645 DOI 10.1007/s00125-010-1901-y SHORT COMMUNICATION Glucagon-like peptide-1 (GLP-1) receptors are not overexpressed in pancreatic islets from patients with severe hyperinsulinaemic
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationNDA NDA APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 022200 NDA APPROVAL Amylin Pharmaceuticals, Inc. Orville Kolterman, M.D. Sr. Vice President, Research & Development
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationAdvances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D
Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationAppendix 4: WHO Classification of Tumours of the pancreas 17
S3.01 The WHO histological tumour type must be recorded. CS3.01a The histological type of the tumour should be recorded based on the current WHO classification 17 (refer to Appendices 4-7). Appendix 4:
More information